Evidence map›Paper›PMID 39812228›Full record

ArticleJournal of medical virology2025

Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results.

Ángela Sánchez-Simarro, Enric Cuevas-Ferrando, Daniel Fernández-Soto, Brayan Grau, Eliseo Albert, Estela Giménez, Ana Isabel Avilés-Alía, Luciana Rusu, Ron Geller, Hugh T Reyburn and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ángela Sánchez-SimarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Enric Cuevas-FerrandoMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.ORCID 0000-0002-0799-009X
Daniel Fernández-SotoDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.ORCID 0000-0002-7325-8614
Brayan GrauInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Eliseo AlbertMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Estela GiménezMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Ana Isabel Avilés-AlíaInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Luciana RusuInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Ron GellerInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Hugh T ReyburnDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.ORCID 0000-0003-3010-4110

Funding

Consejo Superior de Investigaciones CientíficasEuropean CommissionEuropean Regional Development FundInstituto de Salud Carlos IIIMinisterio de Ciencia e Innovación.This research was supported by the Agencia Estatal de Investigación
6 · The paper itself

Abstract

We investigated whether antibody concentrations measured in plasma using the Roche Elecsys® Anti-SARS-CoV-2 S assay (targeting the receptor binding domain, RBD) could estimate levels of Wuhan-Hu-1 and Omicron XBB.1.5 spike-directed antibodies with neutralizing ability (NtAb) or those mediating NK-cell activity. We analyzed 135 plasma samples from 39 vaccinated elderly nursing home residents. A strong correlation was found for NtAb against both Wuhan-Hu-1 (Rho = 0.73, p < 0.001) and Omicron XBB.1.5 (sub)variants (Rho = 0.73, p < 0.001). Moderate positive correlations were observed for NK-cell activity, based on lysosome-associated membrane protein 1 (LAMP1)-producing NK cells stimulated with Wuhan-Hu-1 (Rho = 0.43, p < 0.001) and Omicron XBB.1.5 spike proteins (Rho = 0.50, p < 0.001). Similarly, interferon-gamma (IFN-γ)-producing NK-cell frequencies showed moderate correlations (Wuhan-Hu-1: Rho = 0.43, p < 0.001; Omicron XBB.1.5: Rho = 0.50, p < 0.001). Random Forest models accurately predicted NtAb levels against Wuhan-Hu-1 (R

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAgedAged, 80 and overFemaleHumansImmunoassayKiller Cells, NaturalLysosomal-Associated Membrane Protein 1MaleAntibodies, NeutralizingAntibodies, ViralLAMP1 protein, humanLysosomal-Associated Membrane Protein 1Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2anti‐RBD total antibodiesneutralizing antibodiesNK cellsOmicron XBB.1.5Random Forest modelingRoche Elecsys® anti‐SARS‐CoV‐2 S assaySARS‐CoV‐2

Identifiers

PMID39812228
PMCPMC11734093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.